NCT01433445View on ClinicalTrials.gov

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

June 22, 2020

Study Completion Date

June 22, 2020

Conditions
Idiopathic MyelofibrosisPost Essential Thrombocythemia MyelofibrosisPost Polycythemia-Vera Myelofibrosis
Interventions
DRUG

panobinostat

Given 3 times a week, every other week in 28-day cycles.

DRUG

ruxolitinib

Given twice daily in 28-day cycles.

Trial Locations (10)

21100

Novartis Investigative Site, Varese

39120

Novartis Investigative Site, Magdeburg

50134

Novartis Investigative Site, Florence

55131

Novartis Investigative Site, Mainz

75010

Novartis Investigative Site, Paris

89124

Novartis Investigative Site, Reggio Calabria

94800

Novartis Investigative Site, Villejuif

DUBLIN 8

Novartis Investigative Site, Dublin

Unknown

Novartis Investigative Site, Galway

SE1 9RT

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY